The use of human adipose-derived stem cells based cytotoxicity assay for acute toxicity test

Baer, 2014, Adipose-derived mesenchymal stromal/stem cells: an update on their phenotype in vivo and in vitro, World J. Stem Cells, 6, 256, 10.4252/wjsc.v6.i3.256 Behar, 2012, A method for rapid dose-response screening of environmental chemicals using human embryonic stem cells, J. Pharmacol. Toxicol. Methods, 66, 238, 10.1016/j.vascn.2012.07.003 Bellin, 2012, Induced pluripotent stem cells: the new patient?, Nat. Rev. Mol. Cell Biol., 13, 713, 10.1038/nrm3448 Coleman, 2014, Human-based systems in drug and chemical safety testing–toward replacement, the ‘single R’, ATLA, 42, 357 Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8, 315, 10.1080/14653240600855905 ECVAM, 2010, 1 Eskes, 2009, Proposal for a Brazilian centre on alternative test methods, Altex, 26, 303, 10.14573/altex.2009.4.303 Flecknell, 2002, Replacement, reduction and refinement, Altex, 19, 73 Gimble, 2007, Adipose-derived stem cells for regenerative medicine, Circ. Res., 100, 1249, 10.1161/01.RES.0000265074.83288.09 Guo, 2012, Cytotoxicity and inhibitory effects of low-concentration triclosan on adipogenic differentiation of human mesenchymal stem cells, Toxicol. Appl. Pharmacol., 262, 117, 10.1016/j.taap.2012.04.024 Halle, 2003, The registry of cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals, Altern. Lab. Anim. ATLA, 31, 89, 10.1177/026119290303100204 Hook, 2012, Stem cell technology for drug discovery and development, Drug Discov. Today, 17, 336, 10.1016/j.drudis.2011.11.001 ICCVAM, 2006, vol. 1 ICCVAM, 2006, vol. 2 ICCVAM, 2006 ICCVAM, 2006 ICCVAM, 2006 Kandarova, 2011, Alternative methods in toxicology: pre-validated and validated methods, Interdiscip. Toxicol., 4, 107, 10.2478/v10102-011-0018-6 Kang, 2011, Stem cells in toxicology: fundamental biology and practical considerations, Toxicol. Sci. Off. J. Soc. Toxicol., 120, S269, 10.1093/toxsci/kfq370 Liebsch, 2011, Alternatives to animal testing: current status and future perspectives, Arch. Toxicol., 85, 841, 10.1007/s00204-011-0718-x Luttun, 2005, A perspective on stem cells as a tool for in vitro testing, Altex, 22, 388 Nava, 2012, Controlling self-renewal and differentiation of stem cells via mechanical cues, J. Biomed. Biotechnol., 2012, 1, 10.1155/2012/797410 OECD, 2010 Presgarve, 2008, The need for the establishment of a brazilian centre for the validation of alternative methods (BraCVAM), ATLA, 36, 705 Rajamohan, 2013, Current status of drug screening and disease modelling in human pluripotent stem cells, BioEssays News Rev. Mol. Cell. Dev. Biol., 35, 281, 10.1002/bies.201200053 Russell, 1959 Scanu, 2011, Evaluation of the use of human mesenchymal stem cells for acute toxicity tests, Toxicol. Vitro Int. J. Publ. Assoc. BIBRA, 25, 1989, 10.1016/j.tiv.2011.07.006 Stokes, 2002, Humane endpoints for laboratory animals used in regulatory testing, ILAR J. Natl. Res. Counc. Inst. Lab. Anim. Resour., 43, S31